Crossmark

Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer

Crossref DOI link: https://doi.org/10.1186/s12967-024-05453-8

Published Online: 2024-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wei, Ruicheng

Zhang, Wenli

Yang, Futang

Li, Qianhao

Wang, Qingyu

Liu, Ningshu

Zhu, Jun

Shan, Yongqiang
Funding

Funding for this research was provided by:

Shanghai Henlius Biotech, Inc.
License Information

Text and Data Mining valid from 2024-07-09

Version of Record valid from 2024-07-09
More Information

Article History

Received: 7 February 2024

Accepted: 30 June 2024

First Online: 9 July 2024

Declarations

:

: Animal experiments were conducted in accordance with animal welfare law, approved by Animal Ethical and Welfare Committee of NJMU, and in accordance with the ethical guidelines.

: Not applicable.

: RW, WZ, FY, QL, QW, JZ, and YS are employees of Shanghai Henlius Biotech, Inc. NL is an employee of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Document is current

Any future updates will be listed below